NMC Tightens Oversight of Stem Cell Therapy, Restricts Unproven Use
The National Medical Commission (NMC) has tightened its advisory on stem cell therapy, warning doctors and healthcare institutions against promoting…
Central Drugs Standard Control Organisation
Read More
India Develops Indigenous Heart-Lung Machine with USFDA and CDSCO Approvals
India has taken a major step towards strengthening domestic cardiac medical-device manufacturing with the development of an indigenous heart-lung machine…
SCTIMST Unveils Indigenous Chitra Core Coronary Stent
The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) has marked another milestone in India’s medical-device innovation journey…
CDSCO Limits Supply of IVF Consumables to Registered ART Clinics and Sperm Banks
The Central Drugs Standard Control Organisation (CDSCO) has directed that essential consumables used in in-vitro fertilisation (IVF) procedures can now…
Hospitals May Soon Be Allowed to Import Advanced Medical Devices Directly
India’s drug regulator is considering a proposal that would allow hospitals to directly import high-end medical equipment, eliminating the need…
7-Minute Lung Cancer Immunotherapy Introduced in India
A new under-the-skin immunotherapy treatment for lung cancer, Tecentriq (atezolizumab), has been launched in India, offering a much faster alternative…
Centre Expands Eligibility, Notifies New Recruitment Rules for DCGI Post
The Centre has introduced revised recruitment rules for the Drugs Controller General of India (DCGI), aiming to fix long-standing issues…
NMC Issues Advisory on Stem Cell Therapy Following Supreme Court Ruling
In line with a recent judgment by the Supreme Court of India, the National Medical Commission (NMC) has directed all…
60 Batches, Including Paracetamol and Cefixime, Fail CDSCO Quality Checks
In a recent drug safety update, 60 batches of medicines and medical devices have been classified as Not of Standard…
Dr Reddy’s Launches Low-Cost Semaglutide Generic ‘Obeda’ in India’s Booming GLP-1 Market
Dr. Reddy’s Laboratories has entered the fast-growing GLP-1 therapy segment with the launch of its semaglutide generic, Obeda, for Type…
- 1
- 2